Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target

Ipsen, a company focusing on oncology, has made a deal with Sutro Biopharma for their first antibody drug conjugate (ADC), STRO-003. This ADC targets ROR1, a tumor antigen overexpressed in various cancers. Sutro’s technology allows for precise drug conjugation, potentially making STRO-003 a leading ADC. Ipsen paid $92 million upfront for the rights to STRO-003 and will handle clinical development and commercialization. The deal includes additional milestone payments totaling up to $447 million and royalties from sales. Ipsen’s focus on cancer has been lucrative, with recent acquisitions and partnerships expanding their portfolio and revenue.

Source link

error: Content is protected !!